Human milk exosomal miR-144-5p reduces NEC by modulating TLR4/NF-κB

Neonatal necrotizing enterocolitis (NEC) remains one of pediatrics’ most devastating intestinal disorders, and safer, mechanism-driven therapies are urgently needed. New findings suggest that tiny vesicles naturally present in human breast milk—exosomes—may offer protection by delivering a specific regulatory microRNA.

Researchers report that exosomes enriched with miR-144-5p can help restore the intestinal tight junction barrier, a key defense line that collapses during NEC. By focusing on miR-144-5p, the team moves beyond earlier observations that breast milk exosomes can reduce NEC severity and instead pinpoints a molecular cargo likely responsible for part of that benefit.

The study centers on how NEC damages epithelial integrity and promotes inflammatory signaling. Tight junction disruption is associated with increased permeability, bacterial translocation, and worsening inflammation—conditions that accelerate disease progression in vulnerable newborns. The investigators therefore examined whether miR-144-5p could counter these barrier failures in NEC contexts.

Mechanistically, the work links miR-144-5p action to the TLR4/NF-κB pathway, a well-known inflammatory axis. Toll-like receptor 4 (TLR4) senses danger-associated cues and can trigger NF-κB activation, driving transcription of pro-inflammatory mediators. In NEC, exaggerated signaling through this route contributes to tissue injury and impaired repair.

By modulating this cascade, miR-144-5p appears to dampen downstream inflammatory responses while promoting recovery of junctional structure. The paper’s data indicate that exosomal delivery is central: miRNAs packaged within vesicles can be taken up by recipient cells more efficiently than naked RNA, enabling functional gene regulation in target intestinal compartments.

Together, the results support a model in which breast milk exosomal miR-144-5p alleviates NEC by suppressing TLR4-driven NF-κB activation, thereby reducing inflammatory injury and enabling tighter regulation of epithelial junctions. If translated, such a cargo-guided approach could complement existing supportive NEC treatments.

While additional work will be required to confirm efficacy across models and to evaluate safety, the study provides a clear mechanistic roadmap: therapeutic exosomes or miRNA mimics that bias TLR4/NF-κB activity may be a promising strategy for protecting the neonatal gut.